462: Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL,
Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated
lymphocyte recruitment into the tumor microenvironment following preoperative
sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Sep
24;106(11). pii: dju268. doi: 10.1093/jnci/dju268. Print 2014 Nov. PubMed PMID:
25255802; PubMed Central PMCID: PMC4241888.


463: Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM,
Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor
immunity to prostate cancer through combination immunotherapy with CTLA4 blockade
and GM-CSF. Cancer Res. 2009 Jan 15;69(2):609-15. doi:
10.1158/0008-5472.CAN-08-3529. PubMed PMID: 19147575.


464: Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep. 2007
May;9(3):226-33. Review. PubMed PMID: 17430695.


465: Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Urol Rep. 2006
May;7(3):239-46. Review. PubMed PMID: 16630528.


466: Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol. 2003
Oct;30(5):649-58. Review. PubMed PMID: 14571412.


467: Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG.
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J
Immunol. 2001 Dec 15;167(12):7150-6. PubMed PMID: 11739538.


468: Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev
Immunol. 2000;18:245-73. Review. PubMed PMID: 10837059.


469: Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of
tissue-specific autoimmune prostatitis with prostatic acid phosphatase
immunization: implications for immunotherapy of prostate cancer. J Immunol. 1997 
Oct 1;159(7):3113-7. PubMed PMID: 9317107.